35 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
encephalitis • Mycobacterium ... • Disseminated Mycobacterium ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
encephalitis • Mycobacterium ... • Disseminated Mycobacterium ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Acute Coronary Syndrome - Management Algorithm
 • STEMI
 • NSTEMI (Troponin Positive) / Unstable Angina (UA,
Coronary Syndrome - Management ... : • PCI • Fibrinolysis ... Immediate Medical Therapy ... Optimize Medical Therapy ... #Algorithm #cardiology
Summary of characteristics of Antianginal Drugs

DRUG CLASS, ADVERSE EFFECTS 
 AND DRUG 
INTERACTIONS 

#Antianginal #Medications #Cardiology
#Medications #Cardiology ... #Pharmacology # ... Management #Therapy
Running out of Analgesia and Sedation Medications due to #COVID19?  Anand Swaminathan, MD has put
Swaminathan, MD has put ... Medications #management ... treatment #sarscov2 #criticalcare ... sedative #analgesia #pharmacology
Hyperacute Hypoxemia - Workup and Management
Differential Diagnosis: Aspiration, Flash Pulmonary Edema, Mucous Plugging, Bronchospasm, Pulmonary Embolism,
Hypoxemia - Workup and Management ... Escalation, Tailored Therapy ... PPI Oxygen Therapy ... Workup #diagnosis #Management ... #treatment #criticalcare
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
areas Preferred Therapy ... Patients Preferred Therapy ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Chronic Maintenance Therapy ... mm3 Preferred Therapy ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
days) Preferred Therapy ... or Alternative Therapy ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
BIII) Preferred Therapy ... /ml Preferred Therapy ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology